Estrogen receptors and MPA treatment in metastatic renal carcinoma. A preliminary report

G. Pizzocaro, M. Valente, I. Cataldo, P. Vezzoni, G. Di Fronzo

Research output: Contribution to journalArticle

Abstract

Ten previously untreated patients with metastatic renal carcinoma underwent transperitoneal radical nephrectomy followed by high dosage medroxyprogesterone acetate (MPA) treatment. Estrogen receptors were determined in the specimen of all cases by the dextran-coated charcoal method: both the neoplastic tissue and the healthy parenchyma were tested. The disease progressed in 8 cases, and 2 patients are alive without any evidence of progressive disease 12 and 27 months after the operation. Very low receptor levels were detected in these 2 cases and one of them could be defined as borderline with the authors' threshold criterion. However, receptors were undetectable in neoplastic tissue from 4 to 8 patients who progressed. These questionable results justified the start of a prospective multicentric trial to study in a large number of cases both hormone receptors and clinical receptors and clinical response to hormone therapy in human renal cancer.

Original languageEnglish
Pages (from-to)739-742
Number of pages4
JournalTumori
Volume66
Issue number6
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Estrogen receptors and MPA treatment in metastatic renal carcinoma. A preliminary report'. Together they form a unique fingerprint.

  • Cite this

    Pizzocaro, G., Valente, M., Cataldo, I., Vezzoni, P., & Di Fronzo, G. (1980). Estrogen receptors and MPA treatment in metastatic renal carcinoma. A preliminary report. Tumori, 66(6), 739-742.